{{Rsnum
|rsid=4252125
|Gene=PLG
|Chromosome=6
|position=160731208
|Orientation=plus
|GMAF=0.1612
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=PLG
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 8.0 | 40.7 | 51.3
| HCB | 0.0 | 0.0 | 100.0
| JPT | 0.0 | 0.0 | 100.0
| YRI | 3.4 | 23.1 | 73.5
| ASW | 1.8 | 28.1 | 70.2
| CHB | 0.0 | 0.0 | 100.0
| CHD | 0.0 | 0.0 | 0.0
| GIH | 1.0 | 11.9 | 87.1
| LWK | 2.7 | 16.4 | 80.9
| MEX | 1.7 | 27.6 | 70.7
| MKK | 2.6 | 21.9 | 75.5
| TSI | 8.8 | 40.2 | 51.0
| HapMapRevision=28
}}[[rs4252125]] or [[rs60784473]] are the Asp472Asn described as influencing susceptibility to invasive Aspergillosis  - [http://www.plosgenetics.org/article/info%3Adoi%2F10.1371%2Fjournal.pgen.1000101 plos]

{{PharmGKB
|RSID=rs4252125
|Name_s=PLG: D472N
|Gene_s=PLG
|Feature=
|Evidence=PubMed ID:18566672
|Annotation=An study within a cohort of 236 patients revealed that alleles at this variant significantly affected the risk of developing invasive aspergillosis after allogeneic hematopoietic stem cell transplant.
|Drugs=
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA161845800
}}

{{PMID Auto
|PMID=19124843
|Title=Genome-wide association study of plasma lipoprotein(a) levels identifies multiple genes on chromosome 6q.
|OA=1
}}

{{GET Evidence
|gene=PLG
|aa_change=Asp472Asn
|aa_change_short=D472N
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs4252125
|overall_frequency_n=2809
|overall_frequency_d=10758
|overall_frequency=0.261108
|n_genomes=19
|n_genomes_annotated=0
|n_haplomes=20
|n_articles=1
|n_articles_annotated=1
|in_pharmgkb=Y
|nblosum100=-1
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}